Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Société Francophone de Greffe de Moelle et de Therapie Cellulaire.
Fiche publication
Date publication
août 2021
Journal
Bone marrow transplantation
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LIOURE Bruno, Pr RUBIO Marie Thérèse
Tous les auteurs :
Cornillon J, Daguenet E, Tournilhac O, Blaise D, NGuyen S, Wallet HL, Chevallier P, Dulery R, Forcade E, Srour M, Bazarbachi A, Contentin N, Lioure B, Tinquaut F, Bulabois CE, Rubio MT, Robin M, Bay JO
Lien Pubmed
Résumé
After chemotherapy, fewer than 30% of patients with T-cell lymphoma (T-NHL) are long-term disease-free survivors. Thus, there is a growing interest in allogeneic stem cell transplantation (alloSCT) and its potential graft-versus-lymphoma effect (GVL) for patient with high-risk or recurrent T-NHL with the aim at providing durable disease control in T-NHL. We conducted this registry study to evaluate the outcome of recipients of alternative donor alloSCT for T-NHL. Patients transplanted with Haploidentical donor (Haplo, n = 41) or Umbilical Cord Blood (UCB, n = 54) were analyzed for overall survival (OS), non-relapse mortality (NRM), relapse, and acute/chronic graft-versus-host disease (aGVHD/cGVHD) incidence. At 2 years, OS and PFS were, respectively, of 59% and 53%, without significant difference between Haplo and UCB. In multivariate analysis, disease status at transplant was an independent risk factor for OS and PFS, and aGVHD III-IV was the main factor for OS and NRM. While no major impact of donor source on survival and mortality was noted, this study suggests that alternative donor transplantation appears feasible and offers benefits to patients with T-cell lymphoma.
Référence
Bone Marrow Transplant. 2021 Aug 6;: